Skip to main navigation
Skip to search
Skip to main content
Scholars @ UT Health San Antonio Home
Help & FAQ
English
Español
Home
Profiles
Research units
Publications
Datasets
Search by expertise, name or affiliation
Emerging drugs for the treatment of myelofibrosis
Holly L. Geyer, Ruben Mesa
Research output
:
Contribution to journal
›
Review article
›
peer-review
5
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Emerging drugs for the treatment of myelofibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Myelofibrosis
100%
Symptom
85%
Therapeutic Procedure
71%
Splenomegaly
42%
Combination Therapy
28%
Symptom Management
28%
Targeted Therapy
28%
Patient
28%
Diseases
14%
Life Expectancy
14%
Fibrosis
14%
Mammalian Target of Rapamycin Inhibitor
14%
Hypomethylating Agent
14%
Histone Deacetylase Inhibitor
14%
Anemia
14%
Hsp90 Inhibitor
14%
Drug
14%
Chemotherapeutic Agent
14%
Mortality
14%
Constitutional Symptoms
14%
Telomerase Inhibitor
14%
Janus Kinase 2 Inhibitor
14%
Clinician
14%
Health
14%
Quality of Life
14%
Medication
14%
Ethinylestradiol Plus Megestrol Acetate
14%
Disease Burden
14%
Pharmacology, Toxicology and Pharmaceutical Science
Myelofibrosis
100%
Symptom
85%
Splenomegaly
42%
Diseases
14%
Mammalian Target of Rapamycin Inhibitor
14%
Histone Deacetylase Inhibitor
14%
Anemia
14%
Drug
14%
Fibrosis
14%
Hedgehog
14%
Life Expectancy
14%
Mortality
14%
Heat Shock Protein 90 Inhibitor
14%
Janus Kinase 2 Inhibitor
14%
Myeloproliferative Neoplasm
14%
Telomerase Inhibitor
14%
Ethinylestradiol Plus Megestrol Acetate
14%